SCHEMBL4845586

SCHEMBL4845586

COc1ccc(CNC(=S)[C@@H](CCC2CCCCC2)NC(=O)[C@@H]2CSCN2CCC(C)(C)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.43
CACNA1B Q00975 1/20 0.42
KMT2A Q03164 4/20 0.39
CPB2 Q96IY4 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
LMNA P02545 2/20 0.36
MEN1 O00255 3/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
CCR5 P51681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4845065 0.93 CACNA1B (0.51) ALDH1A1CACNA1BSMN1; SMN2MAPT
SCHEMBL4844373 0.92 ALDH1A1 (0.45) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2
SCHEMBL4847511 0.87 CACNA1B (0.47) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2
SCHEMBL5357927 0.85 CACNA1B (0.51) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2
SCHEMBL4845573 0.84 CACNA1B (0.60) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2
SCHEMBL4836043 0.84 CACNA1B (0.51) ALDH1A1CACNA1BKMT2ACTSLCTSS
SCHEMBL5350467 0.84 CACNA1B (0.49) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2
SCHEMBL5349400 0.84 CACNA1B (0.49) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2
SCHEMBL5345730 0.84 CACNA1B (0.49) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2
SCHEMBL5345749 0.84 CACNA1B (0.49) ALDH1A1CACNA1BKMT2ACPB2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427634-B2 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-23 US claimed
US-20050009890-A1 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. 2005-01-13 US claimed
EP-1097929-A1 AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-05-09 EP claimed
US-7427634-B2 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-23 US disclosed
US-6903119-B1 Amino acid derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-07 US disclosed
US-20050009890-A1 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them ONO PHARMACEUTICAL CO., LTD. 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009890-A1 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them CACNA1I, CACNA1B, CACNA1A ALDH1A1 3828/4885CACNA1B 2/4885KMT2A 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.